PH30120A - Stable pharmaceutical composition of fumagillol derivatives - Google Patents

Stable pharmaceutical composition of fumagillol derivatives

Info

Publication number
PH30120A
PH30120A PH47449A PH47449A PH30120A PH 30120 A PH30120 A PH 30120A PH 47449 A PH47449 A PH 47449A PH 47449 A PH47449 A PH 47449A PH 30120 A PH30120 A PH 30120A
Authority
PH
Philippines
Prior art keywords
pharmaceutical composition
stable pharmaceutical
fumagillol derivatives
fumagillol
derivatives
Prior art date
Application number
PH47449A
Other languages
English (en)
Inventor
Shigeo Yanai
Kazuhiro Saito
Hiroaki Okada
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of PH30120A publication Critical patent/PH30120A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
PH47449A 1992-12-16 1993-12-15 Stable pharmaceutical composition of fumagillol derivatives PH30120A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP33582892 1992-12-16

Publications (1)

Publication Number Publication Date
PH30120A true PH30120A (en) 1996-12-27

Family

ID=18292862

Family Applications (1)

Application Number Title Priority Date Filing Date
PH47449A PH30120A (en) 1992-12-16 1993-12-15 Stable pharmaceutical composition of fumagillol derivatives

Country Status (8)

Country Link
US (1) US5422363A (cg-RX-API-DMAC7.html)
EP (1) EP0602586B1 (cg-RX-API-DMAC7.html)
KR (1) KR940013499A (cg-RX-API-DMAC7.html)
CN (1) CN1093901A (cg-RX-API-DMAC7.html)
AT (1) ATE153854T1 (cg-RX-API-DMAC7.html)
CA (1) CA2111560A1 (cg-RX-API-DMAC7.html)
DE (1) DE69311278T2 (cg-RX-API-DMAC7.html)
PH (1) PH30120A (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5566069A (en) * 1994-03-07 1996-10-15 Monsanto Company Computer network for collecting and analyzing agronomic data
US5699244A (en) * 1994-03-07 1997-12-16 Monsanto Company Hand-held GUI PDA with GPS/DGPS receiver for collecting agronomic and GPS position data
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
US20010025046A1 (en) * 1999-06-24 2001-09-27 Rong(Ron) Liu Self-emulsifying systems containing anticancer medicament
DE60034770T2 (de) 1999-02-26 2008-04-30 Sanofi-Aventis Stabile fumagillin-formulierung
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
AU2002239479B2 (en) * 2000-11-01 2006-11-09 Praecis Pharmaceuticals Incorporated Peptides as Met-AP2 inhibitors
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) * 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US7105482B2 (en) 2000-11-01 2006-09-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
US7001603B2 (en) * 2001-02-28 2006-02-21 Color Access, Inc. Gelled two phase cosmetic compositions
KR100451485B1 (ko) * 2002-03-28 2004-10-06 주식회사종근당 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
US20050239878A1 (en) * 2003-12-29 2005-10-27 Praecis Pharmaceuticals, Inc. Inhibitors of methionine aminopeptidase-2 and uses thereof
AU2008331516B2 (en) * 2007-11-28 2014-01-09 Mersana Therapeutics, Inc. Biocompatible biodegradable fumagillin analog conjugates
CN102123586A (zh) 2008-07-18 2011-07-13 法弗根股份有限公司 治疗超重或肥胖受试者的方法
US8642650B2 (en) 2008-12-04 2014-02-04 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065877A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Methods of treating an overweight or obese subject
KR20120083905A (ko) 2009-10-09 2012-07-26 자프겐 코포레이션 비만의 치료에 사용하기 위한 설폰 화합물
US8815309B2 (en) 2010-01-08 2014-08-26 Zafgen, Inc. Methods of treating a subject with benign prostate hyperplasia
CN102791699B (zh) 2010-01-08 2016-04-06 扎夫根公司 烟曲霉醇型化合物和其制造和使用方法
US20130023513A1 (en) 2010-01-12 2013-01-24 Hughes Thomas E Methods and Compositions for Treating Cardiovascular Disorders
US20130266578A1 (en) 2010-04-07 2013-10-10 Thomas E. Hughes Methods of treating an overweight subject
CN103249735B (zh) 2010-07-22 2016-04-06 扎夫根股份有限公司 三环化合物及其制备和使用方法
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US20140073691A1 (en) 2010-11-10 2014-03-13 Zafgen, Inc. Methods and composition for Treating Thyroid Hormone Related Disorders
WO2012074968A1 (en) 2010-11-29 2012-06-07 Zafgen Corporation Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors
BR112013013411A2 (pt) 2010-11-29 2016-09-13 Zafgen Inc tratamento de obesidade usando administração não diária de 6-0-(4-dimetilaminoetxi) cinamoil fumagilol
US9189078B2 (en) 2010-12-20 2015-11-17 Apple Inc. Enhancing keycap legend visibility with optical components
EP2668169B1 (en) 2011-01-26 2017-11-15 Zafgen, Inc. Tetrazole compounds and methods of making and using same
MX342257B (es) 2011-03-08 2016-09-21 Zafgen Inc Derivados y análogos de oxaspiro [2.5] octano.
BR112013028534A2 (pt) 2011-05-06 2016-09-06 Zafgen Inc compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos
AU2012253759B2 (en) 2011-05-06 2016-01-21 Zafgen Inc. Tricyclic sulfonamide compounds and methods of making and using same
US9242997B2 (en) 2011-05-06 2016-01-26 Zafgen, Inc. Tricyclic pyrazole sulphonamide compunds and methods of making and using same
EP2763671A2 (en) 2011-10-03 2014-08-13 Zafgen, Inc. Methods of treating age related disorders
CA2861390A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
JP2015509102A (ja) 2012-01-18 2015-03-26 ザフゲン，インコーポレイテッド 三環式スルホン化合物並びにその作製および使用方法
KR20150016303A (ko) 2012-05-07 2015-02-11 자프겐 인크. 6-o-(4-디메틸아미노에톡시) 신나모일 푸마지롤의 옥살레이트 염의 다형체 염 및 이의 제조 및 사용 방법
BR112014028041A2 (pt) 2012-05-08 2017-06-27 Zafgen Inc tratamento de obesidade hipotalâmica com inibidores de metap2
EP2850079B1 (en) 2012-05-09 2018-05-02 Zafgen, Inc. Fumigillol type compounds and methods of making and using same
BR112015010225A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos e seus métodos de produção e utilização
JP6169716B2 (ja) 2012-11-05 2017-07-26 ザフゲン，インコーポレイテッド 肝疾患を治療する方法
BR112015010223A2 (pt) 2012-11-05 2017-07-11 Zafgen Inc compostos tricíclicos para o uso no tratamento e/ou controle de obesidade
EP2968250B1 (en) 2013-03-14 2019-06-19 Zafgen, Inc. Methods of treating renal disease and other disorders
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN110769814B (zh) 2017-03-15 2022-10-18 睿升公司 具有高载药量的中链甘油三酯的药物组合物及其相关方法
BE1027390B1 (nl) * 2019-06-21 2021-02-02 Nutrition Sciences Nv Mfca-samenstelling voor gebruik in de aquacultuur van schaaldieren

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0784462B2 (ja) * 1986-07-25 1995-09-13 日清製粉株式会社 ベンゾイミダゾ−ル誘導体
CA1333363C (en) * 1988-01-19 1994-12-06 Judah Folkman Angiogenesis inhibitor comprising fumagillin
PH26256A (en) * 1988-08-12 1992-04-01 Fujisawa Pharmaceutical Co Oxaspiro [2,5] octane derivative
US4954496A (en) * 1988-08-12 1990-09-04 Fujisawa Pharmaceutical Company, Ltd. Cyclohexane derivatives and pharmaceutical compositions
EP0359036B1 (en) * 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
ATE106726T1 (de) * 1988-09-01 1994-06-15 Takeda Chemical Industries Ltd Angiogenese hemmendes mittel.
EP0386667B1 (en) * 1989-03-06 1993-11-18 Takeda Chemical Industries, Ltd. 6-Amino-6-desoxyfumagillols, production and use thereof
EP0387650B1 (en) * 1989-03-06 1993-03-31 Takeda Chemical Industries, Ltd. 6-epifumagillols, production and use thereof
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
TW282399B (cg-RX-API-DMAC7.html) * 1990-05-25 1996-08-01 Takeda Pharm Industry Co Ltd
DE69114782T2 (de) * 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff.

Also Published As

Publication number Publication date
DE69311278T2 (de) 1997-10-30
ATE153854T1 (de) 1997-06-15
EP0602586A3 (cg-RX-API-DMAC7.html) 1994-08-31
EP0602586A2 (en) 1994-06-22
US5422363A (en) 1995-06-06
EP0602586B1 (en) 1997-06-04
CN1093901A (zh) 1994-10-26
DE69311278D1 (de) 1997-07-10
KR940013499A (ko) 1994-07-15
CA2111560A1 (en) 1994-06-17

Similar Documents

Publication Publication Date Title
PH30120A (en) Stable pharmaceutical composition of fumagillol derivatives
CA2156288A1 (en) Glycerol derivative, device and pharmaceutical composition
MA22733A1 (fr) Esters citrates acyles en tant que precurseurs de peracides.
NO934499D0 (no) Ikke-klorfluorcarbonaerosolformuleringer
NO911591D0 (no) Fremgangsmaate for fremstilling av sukrose-6-ester.
PL309812A1 (en) Derivatives of 2-(2-amino- 1,6-dihydro-6-oxopurin-9-ylo) - methoxy-1,3-propanodiole, method of obtaining them and pharmaceutical composition containing such derivatives
SE8206731L (sv) Ester- och amid-derivat av 13,14-didehydro-prostaglandiner
ITRM920761A1 (it) Esteri della l-carnitina e di alcanoil l-carnitine con l'acido glicolico o suoi esteri e composizioni farmaceutiche contenenti tali per il trattamento di affezioni cutanee.
FI895045A0 (fi) Menetelmä ihon kautta annettavan bunatsosiinia sisältävän farmaseuttisen valmisteen valmistamiseksi
MY114765A (en) Preparation for epidermis
FI905748A0 (fi) Foerfarande foer framstaellning av 4-o -fosfater av dopamin och dopaminderivat.
EP0666865A4 (en) PLANT FATTY ACID SYNTHASES.
DK0563112T3 (da) Probucol-holdigt lægemiddel med forøget biotilgængelighed
DE69108616D1 (de) 3.3'-Dithiobis (Propionsäuren) und Estern davon.
KR860700122A (ko) 데글루코테이코플라닌의 카트복실산 에스테르 유도체
MY106615A (en) Stabilized leukocyte-interferons.
NO177484C (no) Fremgangsmåte for fremstilling av et farmasöytisk preparat i form av myke kapsler
OA06792A (fr) Procédé de préparation de dérivés esters d'acides cyclopropane-carboxylique.
NO171912C (no) Fremgangsmaate for fremstilling av 5-klor-3-klorsulfonyl-2-tiofenkarboksylsyreestere
FR2687667B1 (fr) Esters d'acides carboxyliques d'hydroxyphenylalcanols comme stabilisants.
EP0643054A3 (en) Process for the preparation of carbonic acid ester derivatives and intermediates.
FI905930A7 (fi) Menetelmä uusien, farmakologisesti käyttökelpoisten bispilokarpiinihapon esterijohdannaisten valmistamiseksi
BE895712A (fr) Derives de benzo-1,3-thiazine-1,1-dixoyde, leur preparation et leur utilisation
SE8104657L (sv) Injicerbara farmaceutiska kompositioner
OA06793A (fr) Procédé de préparation de dérivés esters d'acides cyclopropane-carboxyliques.